TP53 and acute myeloid leukemia: In the context of NrasG12D/+ associated with p53 mutations, NrasG12D/+ x p53−/− mice developed mixed AML and T-cell malignancy, whereas NrasG12D/+; p53R172H/+ mice rapidly developed a lethal AML with full penetrance and a median survival of ~80 days.